Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation

by Ysios Capital

2 months ago
InceptionBio, Ysios Capital

InceptionBio will focus on identifying, developing and building new companies around high-quality science, with a particular focus on Spain. The fund will primarily invest in technology transfer oppor...

Ysios Capital appoints Joan Perelló as Managing Partner and Arturo Urrios as Partner to drive a new early-stage vertical

by Ysios Capital

3 months ago
Ysios Capital, Joan Perelló, Arturo Urrios

Joan Perelló and Arturo Urrios will lead a new vertical focused on company creation and early-stage biotech projects, with a strong focus on Spain.

Telescope Biotech Fund Announces Annual Results: In Its First Year Since Launch in February 2025, It Achieves a Net Return of +52.5% in Its Gold Class

by Ysios Capital

4 months ago
Telescope Biotech, Andbank Wealth Management, Ysios Capital

La estrategia de inversión especializada ha permitido capitalizar el gran potencial de la innovación biomédica, impulsada además por una oleada de fusiones y adquisiciones.

Inbiomotion, a portfolio company of Ysios Capital, announces the inclusion of the MAF Test in the SEOM guidelines

by Ysios Capital

Inbiomotion has announced that its MAF Test® has been included in the 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, a key consensus document guiding clinical deci...

CDTI Innovación invests in Ona Therapeutics, together with five co-investors

by Professional Newco

8 months ago
Ona Therapeutics, CDTI Innovación, Ysios Capital, Asabys Partners

Ona Therapeutics is a pioneer in the development of first-in-class antibody-drug conjugates (ADCs) that leverage the molecular basis of advanced cancer. Through collaboration with academic and clinica...

SpliceBio closes a $135 million Series B round led by EQT Life Sciences and Sanofi Ventures. Participants include Ysios and Asabys, among others

by Ysios Capital

12 months ago
enfermedad de Stargardt, Ysios Capital, SB-007, SpliceBio, Asabys Partners, EQT Life Sciences, Sanofi Ventures

The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and ...

ReproNovo raises $65 million Series A financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and women’s health

by Ysios Capital

1 year ago
ReproNovo, RPN-001, RPN-002, Ysios Capital

ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced the successful closing of a $65 million Series A financing round. The...

Ysios Capital y Andbank se alían para lanzar el fondo Telescope Biotech Fund

by Ysios Capital

1 year ago
Telescope Biotech Fund, Ysios Capital, Andbank España

Ysios Capital, gestora de venture capital especializada en el sector biotecnológico, y Andbank Wealth Management, gestora de fondos del banco privado Andbank, se han aliado para lanzar el Telescope B...

Ysios Capital participates in $135 million Series B round of Adcendo ApS to fund the development of first-in-class ADCs for the treatment of certain cancers

by Ysios Capital

2 years ago
Adcendo, Ysios Capital, TCGX, ADCs

Adcendo, a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announced the successful closing of an oversubscribed $1...

Memo Therapeutics increases Series C financing to CHF 45 million

by Ysios Capital

2 years ago
AntiBKV, BKV infection, Memo Therapeutics AG, Ysios Capital

Memo Therapeutics, a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20...

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies

by Ysios Capital

2 years ago
ENX-102, Engrail Therapeutics, Ysios Capital

Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close o...

Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, closes a €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures

by Ysios Capital

3 years ago
Ysios Capital, Kynexis, KYN5356, brain diseases, KAT-II

This capital increase will allow Kynexis to advance the development of KYN5356, an innovative quinurenine aminotransferase II (KAT-II) enzyme inhibitor, for the treatment of cognitive impairment assoc...